• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

ETHOS Post-Hoc Analysis: Dave Singh, MD, Highlights Breztri Reduction of Cardiopulmonary Risk in COPD


The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.

Triple inhaled therapy with budesonide/glycopyrrolate/formoterol fumarate was more effective than 2 dual therapy formulations for reduction of the risk of a first cardiopulmonary event in persons with moderate to very severe chronic obstructive pulmonary disease, according to findings of a pivotal post-hoc analysis of the ETHOS phase 3 clinical trial presented at the American Thoracic Society 2024 International Conference. Principal investigator Dave Singh, MD, professor of respiratory pharmacology at the University of Manchester in Manchester, England, highlights the original study, rationale for the post-hoc analysis, and the encouraging findings in an interview with Patient Care® in the short video above.

Singh presented findings on behalf of the COURSE study group from Effect of triple inhaled therapy with budesonide/glycopyrrolate/formoterol fumarate on cardiopulmonary events in chronic cardiopulmonary events in chronic obstructive pulmonary disease: a post-hoc analysis of ETHOS at the 2024 American Thoracic Society International Conference, May 17-22, 2024, in San Diego, CA.

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
© 2024 MJH Life Sciences

All rights reserved.